The history of simple analgesics The Reverend Edward Stone, resting beneath his willow trees in 1758, chewed on a piece of the bark, whereupon the bitter taste "... immediately raised in me a suspicion of its having the properties of the Peruvian bark" 1 . Peruvian bark, which contains quinine, was known to be effective in some cases of ague, a term used to describe a nonspecific group of symptoms including headache, fever and rigors. Many of these patients would have suffered from malaria, hence the response to quinine, but Peruvian bark grew only in South America and an alternative treatment would have been a great breakthrough. Stone conducted experiments over the next five years. He determined that the willow bark was also effective in treating the fever of ague and presented his findings to the Royal Society. His work was published in the transactions but there was little excitement about his discovery for a further 40 years when chemists began pondering the active ingredients of plant-based medication.
The active ingredient of the willow bark is salicylic acid and it had been used before. There are references to its use in the Sumerian civilisation as early as 3000 BC 2 ; the Ancient Egyptians, Romans and Greeks all made medicines from willow bark, while in the 5th century BC, Hippocrates specifically recommended its use for the relief of fever and labour pains. But, as the ancient civilizations declined, salicylic acid disappeared from the records until rediscovered by Edward Stone.
Serious attempts to isolate the active ingredient in the willow were made in the 1820s. Joseph Buchner in Munich isolated crystals he called salicin in 1828, followed by Raffaele Piria producing the more potent salicylic acid in 1838. But it was the Scottish physician, Thomas John Maclagan, searching for a cure for rheumatic fever in Dundee in the 1870s, who popularised the use of salicin for fever. He believed that the disease was due to a parasite and, subscribing to Paracelsus' theory that a cure could usually be found near the source of the disease, was drawn to the willow tree that grew along the fetid river banks -and therefore to salicin. He published his early results in the Lancet in 1876 3 , and within a year the price of salicin had risen to 10 shillings an ounce as many others began using the product.
Meanwhile, as the early steps in the development of aspirin were underway, its future rival began its journey as a result of a prescribing error. In 1886, a patient in Germany presented a prescription for naphthalene for intestinal worms. The chemist accidentally dispensed acetanilide, a by-product of the organic dye industry which was not a pharmaceutical. Fortunately no harm was done; the patient represented a few days later with no resolution of his worms -but his fever was gone. Discovering the error, his doctors Paul Hepp and Arnold Cahn approached the chemists at Kalle and Co. where Hepp's brother worked and suggested that acetanilide might be a useful pharmaceutical. Kalle and Co. conducted a number of investigations into acetanilide and, finding that it did have fever reducing properties, put it on the market as a medication. Anxious to hide its real identity, they sold it as Antifebrine. This became the first brand name to be prescribed by doctors, requiring chemists to order from Kalle and Co. rather than supply the cheaper, readily available generic product -which proved to be a successful ploy.
These developments drew the attention of the organic dye industry and Carl Duisberg, at Friedrich Bayer and Company, conducted further research into their by-products. This led to the discovery of an even more powerful antipyretic with fewer sideeffects -acetophenetidine. Mindful of the successful branding of Antifebrine, they marketed this as Phenacetin. Phenacetin was a big success: Bayer developed a pharmaceutical division of their dye company and a new age began in the pharmaceutical industry with competitive branding and marketing of drugs.
Duisberg became manager of Bayer in 1890 and created a pharmaceutical research group. Three key people, Heinrich Dreser, Arthur Eichengrün and Felix Hoffman were employed in this department, their job being to find a substitute for salicylic acid that was less irritating to the stomach. The result was acetyl salicylic acid which was marketed as Aspirin. Bayer stepped up their marketing, sending free samples to doctors, pharmacists and hospitals. They managed to secure patents in the United States and briefly in Britain, but not in Germany. Faced with increasing competition, the product was altered from a powder to a pressed pill with a distinctive Bayer cross -another attempt to imprint their brand insignia upon the public.
As World War I drew to a close, the world was gripped by the Spanish flu epidemic and aspirin sales rocketed. But this was not good news for Bayer: many believed that the Germans had infected aspirin with the flu virus -and the reparations demanded by the Allies meant an end to any remaining Bayer patents. Aspirin was now being made by many companies selling directly to the public. Phenacetin, although overshadowed by aspirin, had not disappeared, but was widely advertised in over-the-counter headache mixtures which often contained other products such as aspirin and caffeine.
In 1947, David Lester and Leon Greenberg discovered that paracetamol (acetaminophen) was a major, active metabolite of acetanilide (Antifebrine) 4 . Then Bernard Brodie and Julius Axelrod established that paracetamol was also a metabolite of acetophenetidine (Phenacetin), and furthermore, that it was active at lesser doses with no obvious toxicity [5] [6] [7] . Paracetamol was launched as an analgesic in the United States as Tylenol in 1955, and in Britain as Panadol in 1956.
Aspirin, phenacetin, paracetamol and various combinations such as aspirin and caffeine have all been used in the treatment of postoperative pain, especially for minor surgery. Phenacetin was discontinued in the early 1980s due to concerns about nephropathy and carcinogenesis. Aspirin was, for a while, the most popular simple analgesic but has many side-effects, including gastric irritation and an increased risk of haemorrhage. In 1979, Utting and Smith wrote "...though aspirin is not now the most widely used minor analgesic in surgical practice it is still the one with which others are compared" 8 . Paracetamol and newer anti-inflammatory drugs have now largely replaced aspirin as postoperative analgesics, although aspirin is still freely available for use as an over-the-counter medication. More recently aspirin has had a new lease of life as an antithrombotic agent and is now widely used to prevent heart attacks, strokes and other embolic events.
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